In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Altana Signs Up Pharmacia

Executive Summary

Despite having little or no presence in the respiratory market, Pharmacia fought off Novartis, Roche and Aventis to win worldwide marketing right to Altana's roflumilast for COPD and asthma--a drug that could become a blockbuster. Altana reckons that Pharmacia, with no similar products of its own that might compete for attention, is strongly committed to roflumilast's success.

You may also be interested in...

Boehringer's Spiriva: Advancing COPD Therapy

Boehringer Ingelheim's new COPD treatment, Spiriva, could be a blockbuster--particularly if its worldwide marketing partner Pfizer can increase diagnosis of the disease and expand COPD drugs' prescribing base from specialists to GPs. But, complicating matters for Boehringer, Pfizer--through its proposed acquisition of Pharmacia--will also market the PDE-4 inhibitor roflumilast, Altana's next-generation COPD therapy.

Building US Presence

Mid-size European companies look to boost US sales efforts.

Altana Calls Trumps

The success of gastrointestinal drug pantoprazole has turned mid-sized Altana into one of Europe's fastest growing pharmaceutical companies. By re-investing the proceeds from pantoprazole into its own R&D, Altana now has two late-stage follow-ons--ciclesonide and roflumilast--with similar potential to pantoprazole. Rather than simply out-licensing these compounds to larger players, Altana wants a more active role alongside its partners in marketing and selling its own drugs, hoping thereby to establish itself internationally.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts